Background: Fludarabine-based chemoimmunotherapy has well-recognised efficacy and short-term toxicity in the treatment of lymphoid malignancies. However, the presence and significance of prolonged cytopenias after completion of treatment have not been thoroughly quantified.
introduction
The purine nucleoside analogue fludarabine is widely employed in the treatment of patients with previously untreated or relapsed low-grade non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL). Preclinical data on the synergy of fludarabine in combination with other agents [1] led to clinical trials that have established the superiority of combination therapy [2] [3] [4] . The demonstrated efficacy is associated with a generally acceptable short-term toxicity profile. Acute haematological toxicity of regimens combining fludarabine with cyclophosphamide with or without mitoxantrone or rituximab is well recognised with studies reporting rates of grade 3/4 anaemia, neutropenia, and thrombocytopenia of 5%, 40%, and 10%, respectively, during therapy [5, 6] . Indeed, acute myelosuppression is the most common reason for dose reduction or discontinuation of therapy. Along with acute haematological toxic effects, impaired mobilisation of peripheral blood progenitor cells is recognised [7] and secondary myelodysplasia/acute leukaemia has been reported. Of note, the rate of this latter complication is higher than that reported after fludarabine monotherapy, implying damage to haematopoietic precursors, possibly through inhibition of repair of cytotoxic agent-induced DNA damage [8] .
Clinical decision making in the management of patients with low-grade lymphoid malignancies must be informed by data on the incidence and impact of prolonged cytopenias following treatment with fludarabine combination regimens. This has not been reported in detail until now. Furthermore, the definition of complete response (CR) according to recently published guidelines on the diagnosis and treatment of CLL requires the attainment of minimum blood count values [9] . The response categorisation of patients fulfilling criteria for a CR but exhibiting persistent cytopenias is considered a controversial issue in these guidelines, hence highlighting the importance of defining the magnitude of this complication.
methods
Consecutive patients receiving at least one cycle of fludarabine in combination with other cytotoxic agents with or without rituximab for low-grade NHL or CLL from 1996 to 2007 were identified from the institutional database at the Peter MacCallum Cancer Centre. Only patients receiving fludarabine as their first cytotoxic therapy were included, although prior exposure to single-agent chlorambucil for no longer than one month was allowed. Review of patients' medical records was carried out with informed consent under an institutional review board-approved protocol.
Patients were treated with fludarabine 25 mg/m 2 and cyclophosphamide 250 mg/m 2 i.v. for 3 days every 28 days; some patients also received rituximab 375 mg/m 2 on day 1 or mitoxantrone 10 mg/m 2 on day 1. The number of treatment cycles administered was determined by the individual treating physician. The primary end point of this study was the rate of cytopenias present ‡3 months after the final cycle of fludarabine-based combination chemotherapy. This was defined as at least two measurements of haemoglobin (Hb), absolute neutrophil count (ANC), or platelet count below the lower limit of the reference range at our laboratory (Hb = 130 g/l for males £65 years, Hb = 125 g/l for males >65, Hb = 115 g/l for females £65 years, and Hb = 110 g/l for females >65; ANC = 2.0 · 10 9 /l; and platelets = 140 · 10 9 /l). Patient follow-up for cytopenias was censored at the next cytotoxic therapy (including cyclophosphamide for peripheral blood progenitor cell mobilisation) or at the time of disease relapse where there was proven bone marrow involvement or splenomegaly. Other end points examined included time to recovery from cytopenias, as well as the severity of cytopenias and their clinical significance during the first 6 months after treatment, including requirement for transfusion of red cells or platelets, grade 3/4 infections, requirement for granulocyte colonystimulating factor, bleeding episodes, and overall survival.
Alternative causes for post-treatment cytopenias were excluded by bone marrow assessment and by examination of patient records for the presence of possible causative medications, haematinic deficiencies, or the presence of persisting splenomegaly. Autoimmune cytopenias were assessed by standard criteria including bone marrow evaluation for granulocytic maturation arrest (to signify increased peripheral destruction in immune neutropenia) or increased megakaryocyte numbers (to signify increased peripheral platelet destruction in immune thrombocytopenia).
Patient demographics and disease characteristics were summarised using descriptive statistics and comparison between groups of categorical variables or numerical and categorical variables was carried out as appropriate.
All analyses were carried out using the Graphpad Prism software package version 5.0 (GraphPad Software Inc., San Diego, CA).
results
During the study period, 61 patients received fludarabine combination therapy as their first cytotoxic therapy and had blood counts available at 3 months after completion of therapy. The median time from completion of the first fludarabinebased combination treatment to last follow-up was 35 months (range 4-106). Patients were evaluated on the basis of achieving, or failure to achieve, normal peripheral blood counts in all lineages by 3 months (Table 1) . Increasing age was found to be predictive for post-treatment cytopenias, while underlying disease, marrow involvement before fludarabine therapy, and presence of any pretreatment cytopenias were not found to be predictive (although the incidence of pretreatment thrombocytopenia was higher in the patients who subsequently achieved timely count recovery). Treatment-related factors such as the number of cycles administered, requirement for dose delay or reduction during treatment, and the addition of rituximab were not found to have any association with the incidence of cytopenias.
Characteristics of prolonged cytopenias are described in Table 2 . Eight patients were still cytopenic at last follow-up, at median of 8 months (range 3-60 months).
Bone marrow biopsies were carried out for the assessment of response to treatment or for the investigation of persistent cytopenias in 24 of the 26 patients. In one patient, this was due to extensive disease infiltration, and in two patients due to autoimmune destruction. No specific cause was found in the remaining 21 patients; the bone marrow was found to be normocellular (10), regenerative (four), hypocellular (four), or with disease infiltration but insufficient to explain cytopenias (three). No cases of granulocytic maturation arrest (the typical appearance of immune or rituximab-related neutropenia) were identified.
Treatment-related myelodysplastic syndrome/acute myeloid leukaemia (AML) developed in three of the patients with persistent cytopenias at 12, 40, and 94 months (chromosomal analysis disclosed complex abnormalities including a 7q deletion in one case, no mitoses in one case, and 13q deletion in one case) and in one patient without persistent post-treatment cytopenias at 8 months after completion of fludarabine combination therapy (with trisomy 8) (P = 0.30, Fisher's exact test).
The rate of complications in the first 6 months after therapy was compared between the groups. Patients with prolonged cytopenias after treatment had a significantly increased rate of complications ( Table 1 ). The median number of red cell units transfused was 2 (range 2-4). Infectious episodes among patients in the cytopenia group included two episodes of bronchopneumonia and one episode each of Pneumocystis jirovecii pneumonia, bacterial parotitis, and fatal gram-negative sepsis.
The overall survival at 60 months was 61% for patients with post-treatment cytopenias and 96% for those patients with no cytopenias (P = 0.05) (Figure 1 ). The causes of death were progressive disease (one), infection (one), stroke (one), melanoma (one), secondary AML (one), and unknown while in CR (one) in the former group and progressive CLL with Richter's transformation (one) in the latter group.
The rate of re-treatment of lymphoid malignancy was 27% in the cytopenia group (at median 30.8 months) and 23% in the noncytopenia group (at median 21 months); thus it was unlikely that worse survival was solely due to an inability to re-treat.
discussion
In our cohort of 61 patients treated with frontline fludarabine combination regimens for low-grade lymphoid malignancies, 43% of patients experienced cytopenias for >3 months after the completion of therapy. In those patients with delayed blood count recovery, the median time to normalisation of anaemia, neutropenia, and thrombocytopenia was 7, 9, and 10 months, respectively. Eight patients demonstrated no evidence of count recovery by last follow-up (at 3-60 months). Patients with persistent cytopenias were older, suffered a higher rate of complications at 6 months after treatment and experienced worse overall survival at 60 months. Importantly, disease type, underlying marrow involvement, number of fludarabine cycles delivered, and use of rituximab were not found to be predictive for the development of prolonged cytopenias. Although the rate of pretreatment thrombocytopenia was higher in the group of patients who subsequently achieved timely count recovery, this was not explained by planned dose reduction or by the extent of marrow involvement before treatment (there was no difference in these criteria between the groups), and it may be that due to low patient numbers, we have insufficient statistical power to detect a difference.
The aetiology of the cytopenias was unclear in most cases. Of interest, the marrows were not uniformly hypocellular or dysplastic and indeed, no 'typical' bone marrow morphological features were observed. Little is published on the causes of prolonged post-chemotherapy cytopenias; when considered in combination with the data on the increased risk of treatment-related myelodysplasia [8] and the difficulties in progenitor cell mobilisation after fludarabine therapy [10, 11] , our data may imply damage to haematopoietic stem cells enhanced by fludarabine-induced inhibition of DNA repair. In order to address this question, we have embarked on a correlative science research project into the effects of fludarabine on the stem-cell compartment.
Recently updated results on the long-term follow-up of patients with CLL receiving fludarabine, cyclophosphamide, and rituximab as first-line therapy at the MD Anderson Cancer Center have confirmed the potency of this regimen and also described a 19% incidence of cytopenias lasting >3 months, lower than the incidence of 43% in our patients [2] . These CLL, chronic lymphocytic leukaemia; SLL, small lymphocytic lymphoma; WM, Waldenström macroglobulinaemia; NHL, non-Hodgkin lymphoma; MCL, mantle cell lymphoma; FCR 6 M, fludarabine, cyclophosphamide, and rituximab with/without mitoxantrone; FC, fludarabine and cyclophosphamide; RBC, red blood cell; G-CSF, granulocyte colony-stimulating factor.
differences likely relate to the use of different cut-offs used to define cytopenias in the two studies (neutropenia defined as <1 · 10 9 /l in Tam et al. compared with <2 · 10 9 /l in our study and thrombocytopenia defined as <50 · 10 9 /l in Tam et al. compared with <140 · 10 9 /l in our study) as well as to the higher likelihood of autoimmune cytopenias in CLL and the universal use of rituximab by Tam et al. The incidence of infections associated with cytopenias was 8% in the MD Anderson series, lower than our incidence of 19% (5 of 26 patients), and may relate to patient selection bias (the MD Anderson cohort included patients referred for a clinical trial at an academic centre compared with all comers in our cohort), to chance, or to a truly greater incidence of cytopenias in our cohort. Tam et al. found that advanced Rai stage, but not age, constituted a risk factor for prolonged cytopenias; we did not have sufficient data for analysis of the Rai stage of our CLL patients, hence precluding direct comparison. No other study, to our knowledge, has documented haematopoietic toxicity after the completion of fludarabine-based treatment in patients with other low-grade lymphoid malignancies.
According to our data and those from the MD Anderson group, clinicians attempting to document response status 3 months after the completion of CLL treatment, as recommended by recent guidelines [9] , should be aware that cytopenias may be related to treatment rather than to persistent disease. Furthermore, it has been shown that time to disease progression is longer for patients in partial response due to persistent cytopenias than for patients in partial response due to persistent disease [2] . These findings support the published recommendations which stipulate that a bone marrow biopsy be examined at the time of response assessment in the presence of post-treatment cytopenias [9] . To our knowledge, a similar analysis of response to treatment of other low-grade NHL by post-treatment cytopenia status has not been published.
While the present study is limited by its retrospective design, our data contribute to the quantification of the consequences arising from the use of fludarabine-based regimens in low-grade lymphoid malignancy. Clinicians should be aware of the considerable rate of post-treatment cytopenias, as although they mostly resolve spontaneously over time, they may lead to clinically significant complications.
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